Richard Thomas Maziarz, MD discusses the JULIET trial, a phase-2 study of tisagenlecleucel (marketed as KYMRIAH). In this study an international team of researchers evaluated 93 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and found that 52% of those patients responded favorably to the therapy. 40% had a complete response and 12% had a partial response. The study is to be published on-line Dec. 1, 2018 in the New England Journal of Medicine.
In this video, Dr. Maziarz is speaking at the 2018American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego and he explains that chimeric antigen receptor T-cell therapy with tisagenlecleucel induced durable responses among heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma, according to 19-month follow-up results from the phase 2 JULIET trial.
Researchers observed efficacy across all predefined subgroups, including elderly patients and those with clinical or biological factors typically associated with poorer prognosis after receipt of other available treatments.
Kymriah (tisagenlecleucel, Novartis) is an anti-CD19 CAR T-cell therapy approved for treatment of patients aged 25 years or younger with B-cell precursor acute lymphoblastic leukemia that is refractory or in second relapse. The agent also is approved for treatment of patients with DLBCL, high-grade B-cell lymphoma, or DLBCL arising from follicular lymphoma who received two or more lines of systemic therapy.